PDF herunterladen
Nervenheilkunde 2021; 40(10): 752-758
DOI: 10.1055/a-1484-0686
Schwerpunkt

Neuropsychiatrische Störungen bei idiopathischem Parkinson-Syndrom

Neuropsychiatric disorders in Parkinson’s disease
Mario Paulig∗
1   Schön Klinik München Schwabing
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

ZUSAMMENFASSUNG

Unter nicht motorischen Symptomen nehmen neuropsychiatrische Störungen im gesamten Krankheitsverlauf eine herausragende Stellung ein. Sie sind nach wie vor unterdiagnostiziert, haben jedoch erhebliche Auswirkungen auf die Lebensqualität des Patienten und der Angehörigen. Einige Symptome können auf eine ungünstige Prognose verweisen. Die Mehrzahl der neuropsychiatrischen Störungen kann bei einer zielgerichteten klinischen Anamnese unter Einschluss der Angehörigen erfasst werden. Manchmal, z. B. bei kognitiven Defiziten, bedarf es einer neuropsychologischen Testung. Die Behandlung umfasst medikamentöse und nicht medikamentöse Maßnahmen. Allerdings gibt es nur relativ wenig Daten aus kontrollierten Studien, die die Wirksamkeit und Sicherheit einzelner Therapiemaßnahmen belegen.

ABSTRACT

Among non-motor symptoms neuropsychiatric disorders are highly prevalent throughout the course of Parkinson’s disease. They are still underrecognized but have a substantial impact on patient’s quality of life and caregiver burden. Some symptoms may precede adverse outcomes. Most neuropsychiatric symptoms can be revealed by a goal-driven clinical interview including information from the caregivers. In some disorders, e. g. cognitive deficits, neuropsychological testing is mandatory. Treatment includes pharmacological and non-pharmacological approaches. However, currently only a paucity of data from controlled studies support the efficacy and safety of certain therapies.

Schlüsselwörter

Parkinson-Syndrom - Neuropsychiatrie - Depression - Angst - Impulskontrollstörung - Demenz - Psychose

Key words

Parkinson’s disease - neuropsychiatry - depression - anxiety - impulse control disorder - dementia - psychosis


Publikationsverlauf

Artikel online veröffentlicht:
05. Oktober 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Aarsland D, Larsen JP, Tandberg E. et al Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48 (08) 938-942
    CrossrefPubMedGoogle Scholar
  • 2 Hely MA, Morris JG, Reid WG. et al Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-199
    CrossrefPubMedGoogle Scholar
  • 3 Kalia LV, Lang AE. Parkinson’s disease. Lancet 2015; 386 9996 896-912
    CrossrefPubMedGoogle Scholar
  • 4 Pennington C, Duncan G, Ritchie C. Altered awareness of cognitive and neuropsychiatric symptoms in Parkinson’s disease and Dementia with Lewy Bodies: A systematic review. Int J Geriatr Psychiatry 2021; 36 (01) 15-30
    CrossrefPubMedGoogle Scholar
  • 5 Marsh L. Depression and Parkinson’s disease: current knowledge. Curr Neurol Neurosci Rep 2013; 13 (12) 409
    CrossrefPubMedGoogle Scholar
  • 6 Su W, Liu H, Jiang Y. et al Correlation between depression and quality of life in patients with Parkinson’s disease. Clin Neurol Neurosurg 2021; 202: 106523
    CrossrefPubMedGoogle Scholar
  • 7 Wen MC, Chan LL, Tan LC. et al Depression, anxiety, and apathy in Parkinson’s disease: insights from neuroimaging studies. Eur J Neurol 2016; 23 (06) 1001-19
    CrossrefPubMedGoogle Scholar
  • 8 Prell T, Witte OW, Grosskreutz J. Biomarkers for Dementia, Fatigue, and Depression in Parkinson’s Disease. Front Neurol 2019; 10: 195
    CrossrefPubMedGoogle Scholar
  • 9 Shepard MD, Perepezko K, Broen MPG. et al Suicide in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2019; 90 (07) 822-829
    CrossrefPubMedGoogle Scholar
  • 10 Weintraub D, Duda JE, Carlson K. et al CSP 468 Study Group. Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson’s disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2013; 84 (10) 1113-8
    CrossrefPubMedGoogle Scholar
  • 11 Storch A, Schneider CB, Wolz M. et al Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013; 80 (09) 800-9
    CrossrefPubMedGoogle Scholar
  • 12 Seppi K, Ray Chaudhuri K. et al the collaborators of the Parkinson’s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord 2019; 34 (02) 180-198
    CrossrefPubMedGoogle Scholar
  • 13 Menza M, Dobkin RD, Marin H. et al A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72 (10) 886-92
    CrossrefPubMedGoogle Scholar
  • 14 DGN. Leitlinien für Diagnostik und Therapie in der Neurologie. Idiopathisches Parkinson Syndrom. 2016; AWMF-Register-Nummer: 030–010 www.dgn.org
  • 15 Takahashi M, Tabu H, Ozaki A. et al REBORN study group. Antidepressants for Depression, Apathy, and Gait Instability in Parkinson’s Disease: A Multicenter Randomized Study. Intern Med 2010; 58 (03) 361-368
    CrossrefPubMedGoogle Scholar
  • 16 Dobkin RD, Menza M, Allen LA. et al Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry 2011; 168 (10) 1066-74
    CrossrefPubMedGoogle Scholar
  • 17 Moonen AJH, Mulders AEP, Defebvre L. et al Cognitive Behavioral Therapy for Anxiety in Parkinson’s Disease: A Randomized Controlled Trial Mov Disord. 2021 DOI: 10.1002/mds.28533
    CrossrefPubMedGoogle Scholar
  • 18 Scheffels JF, Fröhlich L, Kalbe E. et al Concordance of Mini-Mental State Examination, Montreal Cognitive Assessment and Parkinson Neuropsychometric Dementia Assessment in the classification of cognitive performance in Parkinson’s disease. J Neurol Sci 2020; 412: 116735
    CrossrefPubMedGoogle Scholar
  • 19 Muslimovic D, Post B, Speelman JD. et al Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65 (08) 1239-45
    CrossrefPubMedGoogle Scholar
  • 20 Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. J Neurol Sci 2017; 374: 26-31
    CrossrefPubMedGoogle Scholar
  • 21 Gratwicke J, Jahanshahi M, Foltynie T. Parkinson’s disease dementia: a neural networks perspective. Brain 2015; 138 Pt 6 1454-76
    CrossrefPubMedGoogle Scholar
  • 22 Rolinski M, Fox C, Maidment I. et al Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev 2012; 03: CD006504
    Google Scholar
  • 23 Rothenberg KG, Rajaram R. Advances in Management of Psychosis in Neurodegenerative Diseases. Curr Treat Options Neurol 2019; 21 (01) 3
    CrossrefPubMedGoogle Scholar
  • 24 Mamikonyan E, Xie SX, Melvin E. et al Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord 2015; 30 (07) 912-8
    CrossrefPubMedGoogle Scholar
  • 25 Leung IH, Walton CC, Hallock H. et al Cognitive training in Parkinson disease: A systematic review and meta-analysis. Neurology 2015; 85 (21) 1843-51
    CrossrefPubMedGoogle Scholar
  • 26 Lenka A, Pagonabarraga J, Pal PK. et al Minor hallucinations in Parkinson disease: A subtle symptom with major clinical implications. Neurology 2019; 93 (06) 259-266
    CrossrefPubMedGoogle Scholar
  • 27 Pagonabarraga J, Martinez-Horta S, Fernández de Bobadilla R. et al Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase. Mov Disord 2016; 31 (01) 45-52
    CrossrefPubMedGoogle Scholar
  • 28 Goetz CG, Leurgans S, Pappert EJ. et al Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology 2001; 57 (11) 2078-82
    CrossrefPubMedGoogle Scholar
  • 29 Barrett MJ, Smolkin ME, Flanigan JL. et al Characteristics, correlates, and assessment of psychosis in Parkinson disease without dementia. Parkinsonism Relat Disord 2017; 43: 56-60
    CrossrefPubMedGoogle Scholar
  • 30 Abbasi MH, Esmaeili S, Habibi SA. et al Dilemma in Parkinson’s Treatment; Levodopa Monotherapy May be the Best Choice. J Clin Neurosci 2020; 79: 219-223
    CrossrefPubMedGoogle Scholar
  • 31 Diederich NJ, Fénelon G, Stebbins G. et al Hallucinations in Parkinson disease. Nat Rev Neurol 2009; 05 (06) 331-42
    CrossrefPubMedGoogle Scholar
  • 32 Lizarraga KJ, Fox SH, Strafella AP. et al Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. Clin Geriatr Med 2020; 36 (01) 105-118
    CrossrefPubMedGoogle Scholar
  • 33 Oh YS, Kim JS, Lee PH. Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia. J Mov Disord 2015; 08 (02) 98-102
    CrossrefPubMedGoogle Scholar
  • 34 Zhang JF, Wang XX, Feng Y. et al Impulse Control Disorders in Parkinson’s Disease: Epidemiology, Pathogenesis and Therapeutic Strategies. Front Psychiatry 2021; 12: 635494
    CrossrefPubMedGoogle Scholar
  • 35 Corvol JC, Artaud F, Cormier-Dequaire F. et al DIGPD Study Group. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018; 91 (03) e189-e201
    CrossrefPubMedGoogle Scholar
  • 36 Jeon N, Bortolato M. What drugs modify the risk of iatrogenic impulse-control disorders in Parkinson’s disease? A preliminary pharmacoepidemiologic study. PLoS One 2020; 15 (01) e0227128
    CrossrefPubMedGoogle Scholar
  • 37 Okai D, Askey-Jones S, Samuel M. et al Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson’s disease. Mov Disord 2015; 30 (05) 736-9
    CrossrefPubMedGoogle Scholar